GRAFT POLYMER (UK) PLC |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.5005 GBX | -4.67% |
|
+5.45% | -12.89% |
| 06-07 | Graft Polymer in talks to develop drug delivery systems business | AN |
| 05-31 | Graft Polymer shares up 30% as company files drug delivery patent | AN |
| Sales 2022 | 542K 687K 54.2M | Sales 2023 | 587K 744K 58.7M | Capitalization | 599K 759K 59.86M |
|---|---|---|---|---|---|
| Net income 2022 | -2M -2.54M -200M | Net income 2023 | -3M -3.8M -300M | EV / Sales 2022 | 23.7 x |
| Net cash position 2022 | 1.62M 2.05M 162M | Net cash position 2023 | 121K 153K 12.1M | EV / Sales 2023 | 0.81 x |
| P/E ratio 2022 |
-5.32
x | P/E ratio 2023 |
-0.19
x | Employees | 7 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 43.53% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -4.59% | ||
| 1 week | +5.45% | ||
| Current month | -50.41% | ||
| 1 month | +300.72% | ||
| 3 months | +82.15% | ||
| 6 months | -24.11% | ||
| Current year | -12.89% |
1 week
0.41
0.64
1 month
0.151.41
Current year
0.101.41
1 year
0.104.30
3 years
0.1022.46
5 years
0.1022.46
10 years
0.1022.46
| Managers | Title | Age | Since |
|---|---|---|---|
Victor Bolduev
FOU | Founder | 66 | 31/12/16 |
Yifat Steuer
DFI | Director of Finance/CFO | 53 | 30/04/21 |
Zhanna Vuilova
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Anthony Eastman
SEC | Corporate Secretary | 49 | 17/05/17 |
Victor Bolduev
FOU | Founder | 66 | 31/12/16 |
Yifat Steuer
DFI | Director of Finance/CFO | 53 | 30/04/21 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24/06/24 | 0.5005 | -4.67% | 10 010 805 |
| 21/06/24 | 0.525 | +17.98% | 24,225,150 |
| 20/06/24 | 0.445 | -6.32% | 682,479 |
| 19/06/24 | 0.475 | -5.00% | 13,859,000 |
| 18/06/24 | 0.5 | +5.26% | 17,944,200 |
Delayed Quote London S.E., June 24, 2024 at 02:23 pm
More quotes
Graft Polymer (UK) Plc is a United Kingdom-based multi-sector chemical company. The principal activities of the Company and all its subsidiaries are the research, development and polymer modification technologies and polymer modification techniques. Its core business comprises polymer modification and the development of drug delivery systems. The Company offers bespoke, adapted, and tailored products for customer requests. Its products include GP impact modifiers for polyamide toughening, thermoplastic elastomers (TPE), PP-reinforced compounds, performance additives, polyvinyl chloride (PVC) products, polymeric alloys, vitrimers, wire and cable, non-woven, Halogen-free flame retardants products (HFFR), wood plastic composite board (WPC), recycling, hot melts, roto molding, block-copolymers, pipes, pet modification, porous products, anticorrosive coating, reinforced bioplastic, dispersants, nano graphene. The Company's subsidiaries include Graft Polymer IP Limited and GRAFTBIO Limited.
Sector
Specialty Chemicals
Calendar
25/06/2024
- Q4 2023 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -12.89% | 827K | |
| -4.45% | 19.39B | |
| 0.00% | 4.03B | |
| +10.11% | 1.49B | |
| -1.70% | 1.24B | |
| +18.59% | 953M | |
| -25.14% | 581M | |
| -36.61% | 562M | |
| -24.22% | 254M | |
| -5.77% | 247M |
- Stock Market
- Equities
- GPL Stock
